The correlation between serum 25-hydroxy-vitamin D levels and anti-SARS-CoV-2 S-RBD IgG and neutralizing antibody levels among cancer patients receiving COVID-19 vaccines

被引：8

作者：

Rachman, Andhika ^{[1
]}

Iriani, Anggraini ^{[2
]}

Priantono, Dimas ^{[1
]}

Rumondor, Bayu Bijaksana ^{[3
]}

Betsy, Rachelle ^{[3
]}

Juanputra, Samuel ^{[3
]}

机构：

[1] Univ Indonesia, Dr Cipto Mangunkusumo Gen Hosp, Dept Internal Med, Div Hematol & Med Oncol,Fac Med, Jakarta, Indonesia

[2] YARSI Univ, Dept Clin Pathol, Jakarta, Indonesia

[3] Univ Indonesia, Dr Cipto Mangunkusumo Gen Hosp, Dept Internal Med, Fac Med, Jakarta, Indonesia

来源：

FRONTIERS IN NUTRITION | 2022年 / 9卷

基金：

英国科研创新办公室;

关键词：

vitamin D; cancer; vaccine; SARS-CoV-2; COVID-19; S-RBD IgG; neutralizing antibody; VITAMIN-D SUPPLEMENTATION; 25-HYDROXYVITAMIN D; D DEFICIENCY; D METABOLISM; HUMAN-SKIN; RECEPTOR; CELLS; CHEMOTHERAPY; PREVENTION; CALCIUM;

D O I：

10.3389/fnut.2022.1066411

中图分类号：

R15 [营养卫生、食品卫生]; TS201 [基础科学];

学科分类号：

100403 ;

摘要：

IntroductionDuring the coronavirus disease 2019 (COVID-19) pandemic, vitamin D has been established as an immune-modulator that reduces pro-inflammatory damage which effectively diminish the severity of COVID-19. Vitamin D also has a significant effect against influenza and dengue and increase the seroconversion following influenza vaccination. To date, the role of vitamin D in optimizing the efficacy of COVID-19 vaccines remains unclear. This study aimed to analyze the correlation between serum 25-hydroxy-cholecalciferol or 25(OH)D levels and anti-SARS-CoV-2 S-RBD IgG and neutralizing antibody levels among cancer patients. MethodologyA multicenter cross-sectional study was conducted among solid and hematologic cancer patients who were vaccinated with two doses of the same types of COVID-19 vaccines (either mRNA, non-replicating viral vector, or inactivated) within 6 months. ResultThe median serum 25(OH)D level in 119 cancer patients was 36.36 [IQR = 30.30] ng/mL. The seropositivity of S-RBD IgG and NAb reached 93.3 and 94.1%, respectively. The S-RBD IgG level was significantly higher in the sufficient group (median = 414.07 [1,441.83] AU/mL) than in the deficient group (median = 91.56 [652.00] AU/mL) (p-value = 0.049). Among non-chemotherapy subjects, the anti-SARS-CoV-2 S-RBD IgG levels had a significant positive correlation with 25(OH)D levels (p-value = 0.03; R = 0.588). The NAb levels also showed significantly positive correlation with 25(OH)D level (p-value = 0.005; R = 0.561). The 25(OH)D levels were positively correlated with S-RBD IgG levels among subjects younger than 60 years old (p-value = 0.047; R = 0.136). However, serum 25 (OH)D levels showed no such correlation with S-RBD IgG levels among subjects older than 60 years old (p-value = 0.933; R = 0.136). ConclusionBoth anti-SARS-CoV-2 S-RBD IgG and NAb levels developed moderate correlation with 25(OH)D levels among subjects treated without chemotherapy. The S-RBD IgG levels also had positive correlation with 25(OH)D levels among subjects younger than 60 years old. Thus, we recommended cancer patients to maintain serum 25(OH)D levels above 30 ng/mL (75 nmol/L) to enhance the efficacy of COVID-19 vaccines.

引用

页数：12